Article Tools

Search for Related Articles

  • By Author
  • Search In

Announcements

Science Watch logo

JID Article Named "New Hot Paper" by ScienceWatch.com

Dr. Lauri Hicks' 2007 article on pneumococcal disease has been named a "hot new paper" by Thompson Reuters' ScienceWatch.com. Read a Q&A about the article with Dr. Hicks here

Press Release

Unique Collaboration Charts the Migrations of a Parasite that Affected History
Researchers Sequence Louse DNA from Mummies and Propose New Model for its Development


In the News

Featured in Grist
"Another symptom of swine flu: instant amnesia" May 11, 2009
Swine Influenza Virus: Zoonotic Potential and Vaccination Strategies for the Control of Avian and Swine Influenzas
Eileen Thacker and Bruce Janke
Read the veterinary literature on swine flu and you get a strong sense of what might be called vaccination treadmill: the hog industry is literally scrambling to generate new vaccines for the rapidly evolving flu strains that sweep through CAFOs. Writing in the Journal of Infectious Diseases [PDF] in 2008, Eileen Thacker and Bruce Janke of Iowa State University paint a stark picture: “A number of genetically diverse viruses are circulating in swine herds throughout the world and are a major cause of concern to the swine industry,” they write. “Influenza virus infections in swine and poultry are potential sources of viruses for the next pandemic among humans.”

Featured in New York Times
"Fear of a Swine Flu Epidemic in 1976 Offers Some Lessons, and Concerns, Today" May 8, 2009
Anti‐Ganglioside Antibody Induction by Swine (A/NJ/1976/H1N1) and Other Influenza Vaccines: Insights into Vaccine‐Associated Guillain‐Barré Syndrome
Irving Nachamkin, Sean V. Shadomy, Anthony P. Moran, Nancy Cox, Collette Fitzgerald, Huong Ung, Adrian T. Corcoran, John K. Iskander, Lawrence B. Schonberger, and Robert T. Chen
Irving Nachamkin, a professor of pathology and laboratory medicine at the University of Pennsylvania, examined some 1976 vaccine that had been saved by a scientist in Texas. In a paper published last year in The Journal of Infectious Diseases, he and colleagues reported that mice given the vaccine made antibodies that reacted with gangliosides, which are components of nerve cells. An antibody attack on gangliosides is part of the disease mechanism of Guillain-Barré.

Featured in AFP
"Swine flu vaccine 'could be ready soon'" May 7, 2009
A Broadly Protective Vaccine against Globally Dispersed Clade 1 and Clade 2 H5N1 Influenza Viruses
Mary A. Hoelscher, Neetu Singh, Sanjay Garg, Lakshmi Jayashankar, Vic Veguilla, Aseem Pandey, Yumi Matsuoka, Jacqueline M. Katz, Ruben Donis, Suresh K. Mittal, and Suryaprakash Sambhara
The vaccine Mittal created for the bird flu worked on three different strains isolated over a seven-year period and was described in papers for the Journal of Infectious Diseases and the journal Clinical Pharmacology and Therapeutics.

Featured in Newsweek
"The Path of a Pandemic" http://www.newsweek.com/id/195692
Swine Influenza Virus: Zoonotic Potential and Vaccination Strategies for the Control of Avian and Swine Influenzas
Eileen Thacker and Bruce Janke
Last year researchers from Iowa State University in Ames warned that pigs located in industrial-scale farms were being subjected to influenza infections from farm poultry, wild birds and their human handlers. Writing in The Journal of Infectious Diseases, Eileen Thacker and Bruce Janke said, "As a result of the constantly changing genetic makeup of individual influenza viruses in pigs, the U.S. swine industry is continually scrambling to respond to the influenza viruses circulating within individual production systems."

1 September 2005 Supplement

Volume 192, Number S1
The Journal of Infectious Diseases 2005;192:S71–S79
0022-1899/2005/19205S1-0011$15.00
DOI: 10.1086/431492
SUPPLEMENT ARTICLE

Estimates of Rotavirus Disease Burden in Hong Kong: Hospital‐Based Surveillance

E. Anthony S. Nelson,1

John S. Tam,2

Joseph S. Bresee,6

Kin‐Hung Poon,3

Chi‐Hang Ng,4

Kin‐Sing Ip,5

T. Christopher Mast,7

Paul K.‐S. Chan,2

Umesh D. Parashar,6

Tai‐Fai Fok,1 and

Roger I. Glass6

Departments of 1Paediatrics and 2Microbiology, The Chinese University of Hong Kong, 3Departments of Paediatrics and Adolescent Medicine, Tuen Mun Hospital, 4Departments of Paediatrics and Adolescent Medicine, Queen Elizabeth Hospital, and 5Departments of Paediatrics and Adolescent Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong Special Administrative Region, China; 6Centers for Disease Control and Prevention, Atlanta, Georgia; 7Merck Research Laboratories, West Point, Pennsylvania

Background.We conducted prospective, hospital‐based surveillance for rotavirus disease for a 2‐year period at 4 of 12 public government (Hospital Authority [HA]) hospitals in Hong Kong. It has been estimated that HA hospitals provide 90% of inpatient care in Hong Kong.

Methods.Information was collected for children <5 years old who had a primary or secondary diagnosis of diarrhea or for whom a stool sample was tested for the presence of rotavirus (by enzyme immunoassay) or bacteria (by culture). Surveillance data were compared with routine discharge information from the HA's computerized Clinical Management System (CMS).

Results.During a 2‐year period (1 April 2001 through 31 March 2003), 7391 children were admitted to the hospital with diarrhea or developed diarrhea during their hospital stay. Of these children, 5881 (80%) had a stool sample tested for the presence of rotavirus, and 30% were positive for rotavirus (representing 24% of all diarrhea‐associated admissions). CMS data underreported the total percentage of diarrhea‐associated admissions (15% vs. 20%) and the percentage of diarrhea‐associated admissions that were the result of rotavirus infection (13% vs. 24%). Estimated rates of hospitalization for rotavirus infection (8.8 admissions/1000 children <5 years old and 18.4 admissions/1000 children <1 year old) were 4‐fold higher than our previous estimates, which were determined on the basis of CMS data alone. We estimate that the cumulative risk of hospitalization with rotavirus diarrhea by age 5 years is 1 in 24. Combined active and passive (CMS) surveillance data indicate that 4.6% of all general pediatric admissions to HA hospitals in Hong Kong were associated with rotavirus infection.

Conclusion.Our study combined passive surveillance data from all Hong Kong HA hospitals with active surveillance data from 4 sentinel hospitals. The estimates of rotavirus disease burden obtained will help emphasize the effect of this important disease and create awareness of the potential for rotavirus vaccines. The surveillance model developed could also be a powerful tool for monitoring the effect of a vaccine.

Reprints or correspondence: Prof. E. A. S. Nelson, Dept. of Paediatrics, The Chinese University of Hong Kong, 6/F Clinical Science Bldg., Prince of Wales Hospital Shatin, Hong Kong SAR, China ().

Cited by

E. Anthony S. Nelson, John S. Tam, Ly-Mee Yu, Ying-Chu Ng, Joseph S. Bresee, Kin-Hung Poon, Chi-Hang Ng, Kin-Sing Ip, T. Christopher Mast, Paul K.-S. Chan, Umesh D. Parashar, Tai-Fai Fok, and Roger I. Glass. (2005) Hospital-Based Study of the Economic Burden Associated with Rotavirus Diarrhea in Hong Kong. The Journal of Infectious Diseases 192:s1, S64-S70
Online publication date: 1-Sep-2005.
Laura Jean Podewils, Lynn Antil, Erik Hummelman, Joseph Bresee, Umesh D. Parashar, and Richard Rheingans. (2005) Projected Cost-Effectiveness of Rotavirus Vaccination for Children in Asia. The Journal of Infectious Diseases 192:s1, S133-S145
Online publication date: 1-Sep-2005.
  • Presented in part: 11th Asian Congress of Pediatrics, Bangkok, Thailand, November 2003 (abstract FO‐I‐1).

    Financial support: Hong Kong Research Grants Council; World Health Organization Department of Vaccines and Biologicals; Merck & Co., Inc.

    Potential conflicts of interest: T.C.M. holds equity interest in Merck. E.A.S.N. has received funding and support from Merck for rotavirus surveillance studies, is currently principal investigator of a phase 3 rotavirus vaccine study funded by GlaxoSmithKline, and has received lecture fees and travel support from GlaxoSmithKline. All other authors: no potential conflicts reported.

Close Popup